PARP1 and ovarian cancer: To further assess the possible translational impact of the cooperation between PARPi and METi, we tested this combination in a panel of ovarian cancer cell lines, using PARP inhibitors approved for the treatment of human epithelial ovarian carcinomas (EOC) that represent a fraction of susceptible ovarian carcinomas [30].